Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00486122 · ClinicalTrials.gov registry record · Phase 4
Evaluation of Continuous Symptom Treatment of ADHD
A Phase 4 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 4
- Development phase
- 282
- Enrollment target
NCT00486122 is a Phase 4 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 282 participants.
The verdict
NCT00486122, a Phase 4 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 282 participants
- Enrollment target
Study Summary
The purpose of this study is to test the hypothesis that atomoxetine administered orally, once a day, at doses up to 1.4 mg/kg/day for approximately 6 weeks given in the morning is superior to placebo in children with ADHD.
Interventions
- DRUG Placebo
- DRUG Atomoxetine Hydrochloride
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 282 participants |
| Start Date | 2003-09 |
| Est. Completion | 2004-06 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00486122
The ClinicalTrials.gov registry entry for NCT00486122 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 282 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00486122 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00486122 about?
NCT00486122 is a clinical study titled "Evaluation of Continuous Symptom Treatment of ADHD". The purpose of this study is to test the hypothesis that atomoxetine administered orally, once a day, at doses up to 1.4 mg/kg/day for approximately 6 weeks given in the morning is superior to placebo in children with ADHD.
What is the current status of trial NCT00486122?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 282 participants. The study started on 2003-09. Estimated completion is 2004-06.
What interventions are being tested in trial NCT00486122?
The interventions under investigation include: Placebo (DRUG), Atomoxetine Hydrochloride (DRUG).
Who is sponsoring clinical trial NCT00486122?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.